

Apr. 2020

NIH-NIDDK



CAIRIBU COMMUNITY COMMUNIQUE



Collaborating for the Advancement of Interdisciplinary Research in Benign Urology

MISSION STATEMENT

The CAIRIBU community will foster collaboration across multiple basic science and clinical disciplines to identify and address gaps in knowledge related to the biology, physiology, biochemistry, genomics, genetics, and metabolism of benign urologic diseases. Our overarching goals are to (1) support the next generation of urologic researchers by providing meaningful education and mentoring; (2) enhance knowledge of mechanisms associated with normal development, function, and disease pathology related to the urinary tract, kidney, and prostate; (3) cultivate new research tools and ideas by expanding the collaborative network within and outside of the traditional urologic research field; and (4) use the knowledge and tools generated from our collaborative work to reduce the burden of benign urologic illness and disability by developing and testing new therapies to effectively treat, manage, and prevent these diseases. CAIRIBU aims to create a transdisciplinary infrastructure to promote benign urologic research collaborations, encourage and embrace new investigators into the field, train and mentor the next generation of benign urologic basic scientists and clinician scientists, and develop and share resources and new tools to enhance urology research.

NEW FOA OF INTEREST TO CAIRIBU

This FOA was published 3/31/2020.

<https://grants.nih.gov/grants/guide/pa-files/PAS-20-160.html>

The FOA encourages submission of **pilot and feasibility clinical trials** in humans that will lay the foundation for larger clinical trials related to prevention and/or treatment of diseases and conditions within the mission of NIDDK. The program will support small, short-term clinical trials to acquire preliminary data regarding the effects of intervention, as well as feasibility data related to recruitment and retention, and study conduct. Applications submitted under this FOA should have clearly described aims and objectives and high likelihood that the trial findings will lead to more definitive, hypothesis-driven trials to improve understanding, diagnosis, prevention or treatment of the diseases studied and have the potential to impact clinical practice and/or public health. **Preliminary data regarding intervention efficacy are not required.**

2020 MEETINGS & SYMPOSIA

Apr 24 **Duke University KURE Program annual symposium, "Multidisciplinary Benign Urology Research Day."** Durham, NC. **TRAVEL AWARDS** for early investigators available; must submit abstract by March 30. More info [here](#).

Apr 24-25 **ROCK (Research on Calculus Kinetics) Society annual meeting,** Birmingham, AL. Website link [here](#).

May 15-18 **American Urological Association annual meeting,** Washington, DC. Link [here](#). Deadline for "late-breaking" abstracts is Fri., Feb. 14

May 26-28 **UW-Madison U54 George M. O'Brien Center annual symposium,** Madison, WI

June 4-5 **Washington Univ P20 Developmental Center symposium,** St. Louis, MO. Overall theme is benign urology – aging, immunity, infection, microbiome, and physiology. **TRAVEL AWARDS** for early investigators available. *Stay tuned for more details.*

June 9 **University of Pittsburgh U54 George M. O'Brien Center annual symposium,** Pittsburgh, PA. *Stay tuned for more details*

Aug 25-29 **World Congress on Urology,** Hamburg, Germany

Dec 2-4 **Annual CAIRIBU meeting,** Washington, DC. Details forthcoming. **SAVE THE DATES!!!**

- This event is now a **VIRTUAL MEETING**
- **NO NEED TO TRAVEL!**
- Registration is **FREE** for all
- Register [HERE](#) to get link to participate



Due to the COVID-19 pandemic, the NIH has issued "**News to Know**" for the NIH-funded research community. [SEE NEXT PG](#)

Also, grant applications submitted late for due dates between 3/09/2020 and 5/01/2020 will be accepted through 5/01/2020. See NOT-OD-20-091 [HERE](#).

These 2 events MAY be postponed, but organizers are waiting to see how events unfold in early May.

KEEP THE DATES RESERVED FOR NOW



Kristina Penniston, Director of Interactions
penn@urology.wisc.edu | 608.265.9797
Tamara Bavendam, Project Scientist
tamara.bavendam@nih.gov
Chris Mullins, Program Official
mullinsc@extra.nidk.nih.gov

News to Know

Update for NIH staff from the NIH Office of Extramural Research

03-19-2020

Message to the Community

[Open Mike blog post](#), including Dr. Mike Lauer's video message to the research community on flexibilities during COVID-19. Feel free to share with your grantees. (click image below to play).



Staff Guidance

New [Extramural Intranet Page for Staff with COVID-19 Grants Policy and Guidance](#).

A one-stop location for extramural staff guidance, NIH Guide Notices, and resources related to the management of NIH funding. Recently updated with the following new guidance for staff:

- All peer review meetings in May/June/July to be held using alternate formats. [Read more](#).

New Resource

Lots of Updates on the [COVID-19: Information for NIH Applicants and Recipients](#) webpage.

Includes the latest NIH Guide notices, funding opportunities, and resources for our grants community.

Continually updated. Visit often!

Key Guide Notices

[NOT-OD-20-087](#) — Guidance for NIH-funded Clinical Trials and Human Subjects Studies Affected by COVID-19

[NOT-OD-20-088](#) — Flexibilities for Assured Institutions for Activities of Institutional Animal Care and Use Committees (IACUCs) Due to COVID-19

Staff Training

NIH staff training continues to be available while staff telework.

April 2 [Measuring Research Outputs \(iCite, RCR and translation\)](#)

April 7 [Portfolio Analysis: Introduction \(PA101\)](#)

April 9 [2020 Integrated Core Curriculum Part 2 - Application Submission, Receipt, and Referral](#)

April 16 [iSearch](#)